

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

# Product datasheet for TL311835V

## Cytokeratin 17 (KRT17) Human shRNA Lentiviral Particle (Locus ID 3872)

### **Product data:**

Product Type:	shRNA Lentiviral Particles
Product Name:	Cytokeratin 17 (KRT17) Human shRNA Lentiviral Particle (Locus ID 3872)
Locus ID:	3872
Synonyms:	39.1; CK-17; K17; PC; PC2; PCHC1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	KRT17 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	<u>NM_000422, NM_000422.1, NM_000422.2, BC000159, BC000159.2, BC011901, BC056421, BC072018, BC072019, NM_000422.3</u>
UniProt ID:	<u>Q04695</u>
Summary:	This gene encodes the type I intermediate filament chain keratin 17, expressed in nail bed, hair follicle, sebaceous glands, and other epidermal appendages. Mutations in this gene lead to Jackson-Lawler type pachyonychia congenita and steatocystoma multiplex. [provided by RefSeq, Aug 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

#### **GRIGENE** Cytokeratin 17 (KRT17) Human shRNA Lentiviral Particle (Locus ID 3872) – TL311835V

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US